JAMA Oncol:携带ATM致病性变异的个体患胰腺癌的风险升高了六倍余!

2021-09-22 Nebula MedSci原创

ATM 携带者的胰腺癌相对风险是非 ATM 变异携带者的 6.5 倍

ATM 基因的致病性胚系变异与胰腺癌风险相关。尽管基因检测在大约 1%-3% 的未经选择的胰腺癌患者中检测到了这些变异,但尚未有研究很好地估计携带致病性 ATM 变异的个体患胰腺癌的终生风险。

本研究评估了携带 ATM 基因致病性变异的个体患胰腺癌的年龄特异性外显率。

这是一项多中心的队列研究,分析了来自 130 个携带致病性胚系 ATM 变异的胰腺癌家族的谱系数据。观察年龄特异性胰腺癌风险。使用改进的分离分析估计外显率。

受试队列的胰腺癌发生情况

这 130 个家系(123 个白人家系)共包含 2227 位具有完整记录(家庭关系、胰腺癌诊断、ATM 状态、先证者状态和年龄)的家庭成员(平均 58 岁,1096 位女性),其中 155 位携带 ATM 致病性变异,16 位不携带 ATM 致病性变异,其他个体无检测结果。在这 130 个家系中,217 位个体罹患胰腺癌:78 个家系只有 1 位胰腺癌患者,34 个家系有两位胰腺癌患者,18 个家系有 3 位或更多胰腺癌患者。

有无ATM致病性变异的个体患胰腺癌的累积风险

确诊时的平均年龄为 64 岁(范围 31-98 岁)。50 岁时,携带胚系致病性 ATM 变异的个体患胰腺癌的累积风险估计为 1.1%(95% CI,0.8%-1.3%);70 岁时的累积风险估计为 6.3%;80 岁时的累积风险估计为 9.5%。总体上,ATM 携带者的胰腺癌相对风险是非 ATM 变异携带者的 6.5 倍(95% CI, 4.5-9.5)。

这项多中心队列研究的结果表明,携带胚系致病性 ATM 变异的个体终生患胰腺癌的风险显著增加。

原始出处:

Hsu F, Roberts NJ, Childs E, et al. Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. JAMA Oncol. Published online September 16, 2021. doi:10.1001/jamaoncol.2021.3701

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718867, encodeId=91081e1886756, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Feb 11 12:39:37 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866242, encodeId=c23b18662420c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Nov 21 03:39:37 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342896, encodeId=bc3813428962f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 24 11:39:37 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054013, encodeId=83921054013a5, content=哦组睡了一觉了没人管, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Sep 23 07:02:46 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2022-02-11 cnxcy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718867, encodeId=91081e1886756, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Feb 11 12:39:37 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866242, encodeId=c23b18662420c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Nov 21 03:39:37 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342896, encodeId=bc3813428962f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 24 11:39:37 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054013, encodeId=83921054013a5, content=哦组睡了一觉了没人管, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Sep 23 07:02:46 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-11-21 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718867, encodeId=91081e1886756, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Feb 11 12:39:37 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866242, encodeId=c23b18662420c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Nov 21 03:39:37 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342896, encodeId=bc3813428962f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 24 11:39:37 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054013, encodeId=83921054013a5, content=哦组睡了一觉了没人管, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Sep 23 07:02:46 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1718867, encodeId=91081e1886756, content=<a href='/topic/show?id=d3e9864e750' target=_blank style='color:#2F92EE;'>#致病性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86477, encryptionId=d3e9864e750, topicName=致病性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d36132650190, createdName=cnxcy, createdTime=Fri Feb 11 12:39:37 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866242, encodeId=c23b18662420c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Nov 21 03:39:37 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342896, encodeId=bc3813428962f, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Fri Sep 24 11:39:37 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054013, encodeId=83921054013a5, content=哦组睡了一觉了没人管, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Thu Sep 23 07:02:46 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-09-23 查查佳佳

    哦组睡了一觉了没人管

    0

相关资讯

珐博进 Pamrevlumab 我国获批临床,治疗胰腺癌、肺纤维化

近日,CDE官网显示:FibroGen(珐博进)公司研发的抗体药物 Pamrevlumab 两大适应症进入临床试验默示许可,用于治疗特发性肺纤维化(IPF)以及局部进展期无法切除的胰腺癌(LAPC)患

Radiology:对于胰腺癌患者的风险分层,我们还可以做的更好

胰腺导管腺癌(PDAC)是一种致命性疾病,其5年生存率低于6%。目前只有20%的早期患者可以接受根治性切除手术,而接受根治性切除手术的患者在3年内仍具有高达70%的复发风险。

ATVB:止血生物标志物和静脉血栓栓塞与胰腺癌患者死亡率和化疗反应相关

VTE诊断是与较短的OS和PFS相关。较高的D-二聚体、细胞外囊泡-组织因子活性、PAI-1和sP-选择素基线水平是死亡率增加的独立预后因素,而D-二聚体可预测对姑息性化疗的反应。

Clin Trans Gastroenterology:β6 -整合素可作为胰腺腺癌诊断和预后的血清标志物

胰腺腺癌 (PAC) 的诊断和治疗在全球仍然是一项重大的临床挑战,因为传统的疗法很少能治愈胰腺癌,胰腺癌会导致美国每年约有 30,000 人死亡。

J Exp Clin Canc Res:癌症免疫治疗新突破——CD112R/CD112轴

从与癌症诊断、预后、治疗的关系,带你认识癌症免疫治疗冉冉升起的明日之星——CD112R/CD112轴!

Molecules:番茄红素:以为我只能抗前列腺癌?我还能抗这些癌!

番茄红素的多面效应:通往癌症多靶点治疗的大道!来看看番茄红素如何“大发神威”!